The use of PPARγ agonists to modulate immune responses to malaria was initially motivated by reports demonstrating that PPARγ regulates CD36 transcription and that PPARγ agonists have anti-inflammatory properties [61, 63]. This evidence concerns the gene PPARG and malaria.